Article | May 26, 2022

How To Build Mutually Beneficial Relationships With Advocacy Groups

Source: Worldwide Clinical Trials

By Derek Ansel, MS, CCRA, Senior Director, Therapeutic Strategy Lead, Rare Diseases, Worldwide Clinical Trials

Building-strong-relationships-between-clinical-and-IT-staff

We know a road paved with good intentions can still lead to…well, not the destination you intended. The emphasis on patient-focused trials which reduce barriers to participation has increased access for patients, but it has also led to one-sided, transactional relationships between industry and advocacy groups. To better meet the needs of the patients we both ultimately serve, we need to focus on building mutually beneficial, sustainable relationships which achieve the goals of both sets of stakeholders.

Having worked in rare disease clinical research for over ten years in a very patient-focused role, I have worked with many advocacy groups both large and small and have found one thing to be certain—working together, we achieve far more than working separately. It is a worthwhile time commitment for pharma, biotech, and CROs to invest in the advocacy groups we work with—but how?

VIEW THE ARTICLE!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Clinical Leader